DOCSLIB.ORG

MEDICAL CANNABIS in EUROPE: the Markets & Opportunities SECOND EDITION

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
MEDICAL CANNABIS in EUROPE: the Markets & Opportunities SECOND EDITION MEDICAL CANNABIS IN EUROPE: The Markets & Opportunities SECOND EDITION In-depth look at key European markets and the regulations companies need to understand to tap these revenue opportunities © 2020 Anne Holland Ventures Inc. All Rights Reserved Medical cannabis for German patients We purchase and import EU-GMP medical cannabis into Germany and sell to pharmaceutical wholesalers who supply to pharmacists Subscribe to our newsletter at amp-eu.com/learnmore Medical Cannabis in Europe: The Markets and Opportunity mjbizdaily.com/intl TABLE OF CONTENTS WLECOME LETTER 5 EU MARKET AT A GLANCE 9 GERMANY 14 ITALY 43 THE NETHERLANDS 55 DENMARK 65 CZECH REPUBLIC 74 AUSTRIA AND SWITZERLAND 78 OTHER SMALL MARKETS 80 3 Copyright 2020, Marijuana Business Daily, a division of Anne Holland Ventures Inc. You may NOT copy this report, or make public the data and facts contained herein, in part or in whole. For more copies or editorial permissions, contact [email protected] or call 720.213.5992 ext. 1. RESEARCH DRIVEN LEDs for Compact Plants with High THC/CBD Outputs UV-A Enriched Spectrum for Increased Cannabinoid Production GACP/GMP Facility Suitable Since 2009 we have been committed to creating the best LED grow lights on the market so as to enable growers to increase yields, quality and energy savings. With the largest patent portfolio in the cannabis lighting industry, we are the pioneers of the high quality horticultural LED solutions. 31% 16% 28% more more total more compact plants cannabinoid flowers yield ...than with HPS. 7% 6% 4% more more total more compact plants cannabinoid THC yield ...than with competitor’s LEDs. Get a FREE Light Plan Today! [email protected] www.valoya.com Medical Cannabis in Europe: The Markets and Opportunity mjbizdaily.com/intl MEDICAL CANNABIS IN EUROPE: THE MARKETS AND OPPORTUNITY One year after the first edition of this report, Europe continues being a key region for international cannabis companies trying to scale globally and a place that has provided numerous opportunities to local entrepreneurs. With a population of more than 500 million, generally high per-capita gross domestic product (GDP) and health-insurance coverage for cannabis in several countries, Europe is seen by many in the industry as having the potential to one day be a larger market long term than the U.S. and Canada combined. How things evolved in Europe in the past year adds to that optimistic outlook, with sales Alfredo Pascual in Germany and Italy—the two largest markets on the continent—posting double-digit, MJBizDaily International Analyst year-over-year growth in 2019. While the long-term expectation of Europe being a massive medical—and, eventually, recreational—cannabis industry continues to show promise, this report highlights the reality of the market today, including the actual sales and the regulatory frameworks that exist in the main European markets. For 2019, Marijuana Business Daily estimates total sales of medical cannabis in Europe ranged from 230 million and 250 million euros ($251 million-$273 million), with roughly half those figures represented by the markup pharmacies in countries such as Germany and Italy added before dispensing the products. For context, total medical cannabis sales in Europe in 2019 were less than half the sales that took place in the U.S. state of Arizona (population 7.3 million) last year. The European market also continues to present a unique set of challenges for companies and investors looking to make inroads there. The continent cannot be viewed as a single jurisdiction, because a diversity of languages and cultures exist across national boundaries. Meaningful European-wide regulations are scarce, and individual cannabis frameworks vary drastically. This report provides industry leaders and investors interested in the European markets with a realistic estimate of current market sizes and a detailed analysis of the countries where the most opportunities exist. What it will not provide is long-term, uncertain projections that have no basis in data. 5 Copyright 2020, Marijuana Business Daily, a division of Anne Holland Ventures Inc. You may NOT copy this report, or make public the data and facts contained herein, in part or in whole. For more copies or editorial permissions, contact [email protected] or call 720.213.5992 ext. 1. Medical Cannabis in Europe: The Markets and Opportunity mjbizdaily.com/intl In 2019, sales of medical cannabis in Europe continued to be centered on Germany. Other countries showed positive signs, advancing with legislation that either allowed national production or prescription, but those markets are far from developed. For producers of medical cannabis that are able to comply with stringent quality requirements, exporting to Germany continues to be the most obvious option, as the country will depend exclusively on imports until at least the end of 2020 to meet its domestic demand. However, one year after the first edition of this report, we no longer have a solid sense of the ever-growing number of countries and companies trying to export to Germany— there are just too many of them. At the same time, the number of actual companies whose products reach German patients remains just a few and largely unchanged from last year edition. It’s important to note that whenever we mention medical cannabis in Europe, we are referring to products prescribed by physicians and typically dispensed in pharmacies. Industrial hemp and low-THC CBD consumer products are not part of this report, which also doesn’t cover noncommercial access to cannabis, for instance, through home growing or marijuana social clubs. Because of the ever-changing nature of cannabis regulations and the fact most available official sales data is only through the end of 2019 for most jurisdictions at the time of publication, information in this report should be assumed to be updated through 2019 unless otherwise specified. I’d like to give a special thank you to the government agencies and officials that provided official data or clarifications, and to all the local experts and industry insiders who helped to make this comprehensive report possible, including Andrew de Roy for his insights on Poland. If you have any questions or comments, feel free to reach out to me at [email protected]. Alfredo Pascual International Analyst 6 Copyright 2020, Marijuana Business Daily, a division of Anne Holland Ventures Inc. You may NOT copy this report, or make public the data and facts contained herein, in part or in whole. For more copies or editorial permissions, contact [email protected] or call 720.213.5992 ext. 1. Leading German manufacturer, importer, and distributor of medical cannabis THE COMPANY OUR BUSINESS MODEL Founded in 2017, Cansativa is a GMP-certified Global footprint – We source medical pharmaceutical company and holds a GDP cannabis globally and collaborate with pharmaceutical wholesale license to trade in several high-class and well-known controlled substances. From its headquarters in medical cannabis suppliers Mörfelden-Walldorf, Germany, Cansativa and its subsidiaries work to professionalize the medical One-stop shop – We positioned Can- cannabis market, eliminate stigmatization and to sativa as the leading medical cannabis permanently serve patients needs. As an owner- focused wholesaler with an extensive managed company, our growth target is linked to customer base and a broad product a long-term vision – continuously setting industry- portfolio to serve patients needs wide benchmarks. Know-how – Due to our professional Since the very beginning, Cansativa has operated integrated inhouse solutions we became its own distribution and fulfillment center, and as experts within the European medical one of its industry’s “first movers”, it has become a cannabis industry leading manufacturer, importer and distributor of medical cannabis in Germany. From its locations Patients first – Our top priority is in Mörfelden-Walldorf and Frankfurt am Main, the process and product quality without company supplies pharmacies and pharmaceutical compromises to ensure a save product wholesalers nationwide. CONTACT US! www.cansativa.de or send an email to [email protected] Founding of Cansativa GmbH in Receival of EU GMP manufacturing Frankfurt am Main and receival of and import license for both EU GDP wholesale license. Cansativa GmbH facilities 2017 2018 2019 2020 Processing of first import Became leading medical cannabis one-stop and start of operations shop with an extensive product portfolio Johann Benedikt Sons Jakob Christian Sons Chief Executive Officer and Founder General Counsel and Founder © Cansativa GmbH Hessenring 15i 64546 Mörfelden-Walldorf www.cansativa.de Die Cansativa GmbH mit Sitz in Frankfurt am Main ist eingetragen im Handelsregister des Amtsgerichtes Frankfurt am Main unter HRB 108385. beyond pioneering Health, especially in these strange and uncertain times, has become everyone’s primary concern. We are therefore grateful that the production and distribution of Bedrocan’s medicinal cannabis to patients around the world will continue as usual. In fact, in some countries, new distribution channels have emerged to meet the needs of vulnerable patients. Also during a crisis like the COVID-19 pandemic, we are committed to deliver standardised cannabis of Bedrocan is the oldest company in the world to pharmaceutical quality. Each product has a distinct provide several chemically different cannabis chemical profile, with a consistent, defined
Load more

Recommended publications
  • 2017 Global Drug Survey
    Prepared by the GDS Core Research Team Dr Adam Winstock, Dr Monica Barratt, Dr Jason Ferris & Dr Larissa Maier Global overview and highlights N > 115,000 Global Drug Survey GDS2017 © Not to be reproduced without authors permission Hi everyone On behalf of the GDS Core Research Team and everyone of our amazing international network partners and supportive media organisations we’d like to share our headline report deck. I know it won’t have everything that everyone wants but we are hopeful it will give people an idea of how the world of drugs is changing and highlight some of the key things that we think people can better engage with to keep themselves and those they care for safe. Once we cleaned the data from 150,000 people we chose to use data from just under 120,000 people this year for these reports. We have data reports addressing 18 different areas for over 25 countries. We can only share a fraction of what we have here on the site. However, we are very open to sharing the other findings we have and would ask researchers and public health groups to contact us so we can discuss funding and collaboration. We have almost completed designing GDS2018 so that we can start piloting early and give countries where we have not yet found friends to reach out to us. We particularly want to hear from people in Japan, Eastern Europe, Africa and the Middle East. Dr Adam R Winstock Founder and CEO Global Drug Survey Consultant Psychiatrist and Addiction Medicine Specialist Global Drug Survey GDS2017 © Not to be reproduced without authors permission We think this will be interesting.
    [Show full text]
  • Access to Medicinal Cannabis: Meeting Patient Needs
    Access to medicinal cannabis: meeting patient needs All-Party Parliamentary Group for Drug Policy Reform Inquiry Report “The enjoyment of the highest attainable standard of health is one of the fundamental rights of every human being without distinction of race, religion, political belief, economic or social condition.” Constitution of the World Health Organisation drawn up in 1946 in conformity with the Charter of the United Nations Foreword For six years, the All-Party Parliamentary Group for Drug Policy Reform has worked for an end to the “war on drugs” driven by the USA and supported by the UN. In our “Guidance on Interpreting the UN Drugs Conventions”, we called for three major changes: 1. evidence-based drugs policy; 2. policy that genuinely promotes the health and welfare of mankind driven by human rights and public health values; 3. flexibility for Member States to develop drug policy within the UN Conventions based on our four “Guidance” principles. We have had meetings with the President of the UN Economic and Social Council (ECOSOC); the Executive Director of the UN Office on Drugs and Crime (UNODC); and the Deputy Secretary General of the UN. We have organised international meetings of Ministers and senior officials in Westminster and spoken at international meetings in New York, Brussels and Cartagena, Colombia. At the UN General Assembly Special Session (UNGASS) held in April 2016, we witnessed both the USA and the UN leadership reject a moralistic and prohibitionist approach to the global drug problem. Instead, the UN and US leaders called for all our proposed changes to global drugs policy.
    [Show full text]
  • PDF (Book of Abstracts)
    Ninth Annual Conference of the International Society for the Study of Drug Policy Ghent (Belgium) – 20 – 22 May 2015 Venue: Het Pand With the financial support of Book of Abstracts i ISSDP conference 20-22 May 2015 Book of Abstracts Table of Contents KEYNOTE SPEAKERS ......................................................................................................................................... 5 ABDOOL, REYCHAD ................................................................................................................................................ 6 BERRIDGE, VIRGINIA .............................................................................................................................................. 7 KRAUS, LUDWIG .................................................................................................................................................... 8 MASAO, FRANK ..................................................................................................................................................... 9 MOORE, DAVID ................................................................................................................................................... 10 TOUFIQ, JALLAL ................................................................................................................................................... 11 ORAL PRESENTATIONS ................................................................................................................................... 13 AHMED, TANVIR
    [Show full text]
  • Cannabis Regulation in Europe: Country Report Denmark
    COUNTRY REPORT | February 2019 Cannabis Regulation in Europe: Country Report Denmark Maj Nygaard-Christensen and Vibeke Asmussen Frank Aarhus University ideas into movement Introduction This report examines policy and practice relating to the regulation of cannabis in Denmark. It was produced as part of a study of cannabis regulation models in Europe, funded by the European Commission and led by the Transnational Institute in Amsterdam. The broader study examines and compares experiences from European countries’ experiments with cannabis regulation, including trial proposals for legalisation or decriminalisation of cannabis use, with a particular focus on larger cities in six countries. Denmark has no legal regulation regarding recreational cannabis use, and possession, production, import/export, and buying and selling of cannabis is illegal (Dahl and Frank 2012: 13). This overview of the legal and policy framework for the regulation of cannabis first introduces the policy shifts in cannabis control in Denmark, reviews the political positions on possibilities for legalisation or decriminalisation, and the international context influencing these. It then offers an analysis of how policy and police crackdowns on the open-air cannabis market in Christiania in Copenhagen led to a dispersal and restructuring of the market, with the entry of new criminal gangs. This part of the report indicates an increasingly repressive cannabis policy in Denmark, although there are some openings in the form of a trial for medicinal cannabis commencing in 2018, and a proposed model for legalised cannabis in Copenhagen Municipality. From Tolerant to Repressive Cannabis Control Cannabis falls under the 1955 Euphoriant Substances Act, which is used for minor offences that can be punished with up to a two-year prison term, and the penal code’s §191 from 1969, which refers to the organised sale and possession of larger amounts of narcotics.
    [Show full text]
  • Impact of Lipid Sources on Quality Traits of Medical Cannabis-Based Oil Preparations
    molecules Article Impact of Lipid Sources on Quality Traits of Medical Cannabis-Based Oil Preparations Alberto Ramella 1, Gabriella Roda 2, Radmila Pavlovic 3,*, Michele Dei Cas 4 , Eleonora Casagni 2, Giacomo Mosconi 3, Francisco Cecati 5, Paola Minghetti 2 and Carlo Grizzetti 6 1 Farmacia Dott.ri Giuliana e Alberto Ramella–SAS, Via A. Diaz 1, 21021 Angera (VA), Italy; [email protected] 2 Department of Pharmaceutical Sciences, Università degli Studi di Milano, Via L. Mangiagalli 25, 20133 Milan, Italy; [email protected] (G.R.); [email protected] (E.C.); [email protected] (P.M.) 3 Department of Health, Animal Science and Food Safety, University of Milan, 20133 Milan, Italy; [email protected] 4 Department of Health Sciences, Università degli Studi di Milano, Via A.di Rudinì 8, 20142 Milan, Italy; [email protected] 5 INTEQUI-CONICET, Faculty of Chemistry, Biochemistry and Pharmacy, National University of San Luis, Almirante Brown 1455, San Luis CP 5700, Argentina; [email protected] 6 S.S.D. Cure Palliative e Terapia del Dolore, Ospedale di Circolo–Fondazione Macchi, ASST Sette Laghi, Viale L. Borri 57, 21100 Varese, Italy; [email protected] * Correspondence: [email protected] Academic Editor: Maria Carla Marcotullio Received: 2 June 2020; Accepted: 29 June 2020; Published: 30 June 2020 Abstract: The feasibility of the use of two lipid sources and their impact on the cannabinoid profile, terpene fingerprint, and degradation products in medical cannabis oil preparations during 3 months of refrigerated storage time were investigated. LCHRMS-Orbitrap® and HS-SPME coupled to GC-MS for the investigation of targeted and untargeted cannabinoids, terpenes, and lipid degradation products in Bedrocan® and Bediol® macerated oils were used as analytical approaches.
    [Show full text]
  • ©Copyright 2008 Sunil Kumar Aggarwal
    ©Copyright 2008 Sunil Kumar Aggarwal The Medical Geography of Cannabinoid Botanicals in Washington State: Access, Delivery, and Distress Sunil Kumar Aggarwal A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington 2008 Program Authorized to Offer Degree: Geography University of Washington Graduate School This is to certify that I have examined this copy of a doctoral dissertation by Sunil Kumar Aggarwal and have found that it is complete and satisfactory in all respects, and that any and all revisions required by the final examining committee have been made. Chair of the Supervisory Committee: ___________________________________________________ Jonathan Mayer Reading Committee: __________________________________________________ Jonathan Mayer _________________________________________________ Richard Morrill ___________________________________________________ Craig ZumBrunnen ___________________________________________________ Gregory Carter ___________________________________________________ Ethan Russo Date:__________________________ In presenting this dissertation in partial fulfillment of the requirements for the doctoral degree at the University of Washington, I agree that the Library shall make its copies freely available for inspection. I further agree that extensive copying of the dissertation is allowable only for scholarly purposes, consistent with “fair use” as prescribed in the U.S. Copyright Law. Requests for copying or reproduction of this dissertation
    [Show full text]
  • PTW 1-19 INH 190318 V07.Indd
    Herausgegeben von der Schweizer Charta für Psychotherapie in der Assoziation Schweizer Psychotherapeutinnen und Psychotherapeuten Psychotherapie-Wissenschaft Science Psychothérapeutique WWW.PSYCHOTHERAPIE-WISSENSCHAFT.INFO Kultur, Religion und Psychotherapie Culture, religion et psychothérapie Cultura, religione e psicoterapia 9 . Jahrgang Heft 1 / 2019 Herausgegeben von Mario Schlegel und Nicola Gianinazzi ISSN 1664-9583 Psychosozial-Verlag Impressum Psychotherapie-Wissenschaft Abo-Verwaltung ISSN 1664-9583 (Print-Version) Psychosozial-Verlag ISSN 1664-9591 (digitale Version) [email protected] 9. Jahrgang Heft 1/2019 https://doi.org/10.30820/1664-9583-2019-1 Bezugsgebühren Jahresabonnement 44,90 € (zzgl. Versand) Herausgeber Einzelheft 24,90 € (zzgl. Versand) Schweizer Charta für Psychotherapie in der Assoziation Studierende erhalten gegen Nachweis 25 % Rabatt. Schweizer Psychotherapeutinnen und Psychotherapeuten Das Abonnement verlängert sich um jeweils ein Jahr, sofern nicht eine Geschäftsstelle ASP Abbestellung bis acht Wochen vor Ende des Bezugszeitraums erfolgt. Riedtlistr. 8 ASP-Mitglieder wenden sich wegen des Abonnements bitte CH-8006 Zürich direkt an die ASP. Tel. +41 43 268 93 00 www. psychotherapie.ch Anzeigen Anfragen zu Anzeigen bitte an den Verlag: Redaktion [email protected] Rosmarie Barwinski, Zürich Es gelten die Preise der auf www.psychosozial-verlag.de Nicola Gianinazzi, Lugano einsehbaren Mediadaten. Astrid Grossert, Basel ASP-Mitglieder wenden sich bitte direkt an die Redaktion. Margit Koemeda, Zürich Mario Schlegel, Zürich Digitale Version Peter Schulthess, Zürich Die Zeitschrift Psychotherapie-Wissenschaft ist auch online einsehbar: www.psychotherapie-wissenschaft.info [email protected] www.psychotherapie-wissenschaft.info Hinweise für AutorInnen befinden sich auf der Homepage der Zeitschrift: www.psychotherapie-wissenschaft.info Die Beiträge dieser Zeitschrift sind unter der Creative Commons Attribution-NonCommercial-NoDerivs 3.0 DE Lizenz lizensiert.
    [Show full text]
  • EMCDDA Cannabis Reader
    ISSN 1606-1691 A cannabis reader: global issues and local experiences 05 06 15 TD-32-07-001-EN-C About the EMCDDA The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is one of the European Union’s decentralised agencies. Established in 1993 and based in Lisbon, it is the central source of comprehensive information on drugs and drug addiction in Europe. The EMCDDA collects, analyses and disseminates factual, objective, reliable and comparable information on drugs and drug addiction. In doing so, it provides its audiences with an evidence-based picture of the drug phenomenon at European level. The Centre’s publications are a prime source of information for a wide range of audiences including policy-makers and their advisers; professionals and researchers working in the drugs field; and, more broadly, the media and general public. EMCDDA monographs are comprehensive scientific publications containing thematic papers prepared in the context of the Centre’s activities. Topics cover a wide range of issues relating to science, policy, epidemiology and best EMCDDA practice. MONOGRAPHS A cannabis reader: global issues and local experiences Price (excluding VAT) in Luxembourg: EUR 20 per volume MONOGRAPHS EMCDDA VOL. I VOL. 8 8 I VOLUME EMCDDA MONOGRAPHS A cannabis reader: global issues and local experiences Perspectives on cannabis controversies, treatment and regulation in Europe Editors Sharon Rödner Sznitman, Börje Olsson, Robin Room 8 I VOLUME Legal notice This publication of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is protected by copyright. The EMCDDA accepts no responsibility or liability for any consequences arising from the use of the data contained in this document.
    [Show full text]
  • Medicinal Use of Cannabis 3Rd Edition
    M E M O R A N D U M Medicinal use of Cannabis 3rd edition 2015 04/12/2015 Medicines Control & Inspection File no.2013113424/ Axel Heides Gade 1 DK-2300 Copenhagen S Frank Bøgh Madsen [email protected] Email: [email protected] Page 2 04/12/2015 Danish Medicines Agency Contents 1. Introduction ................................................................................................ 3 2. The body's own cannabinoids and receptors .............................................. 3 3. Knowledge about intoxicating and harmful effects and the prevalence of Cannabis......................................................................................................... 4 3.1. The Dutch Ministry of Health's brochure about side effects of medicinal use of Cannabis .......................................................................................... 5 4. Rules about Cannabis as a euphoriant substance ....................................... 6 4.1. List A – Cannabis ............................................................................... 6 4.2. List B – THC in pure form and other cannabinoids ............................ 7 4.3. CBD – in pure form or in hemp products ............................................ 8 5. Positive effects of medicines containing active substances from Cannabis and clinical trials ............................................................................................ 8 5.1. Other scientific evidence about Cannabis and cannabinoids ............ 10 6. Rules about medicines requiring a marketing authorisation (Sativex®)
    [Show full text]
  • ANALYSIS of EXPERIENCE COUNTRIES of the WORLD on LEGALIZATION of MEDICAL CANNABIS Nemchenko A
    Фізіологія, валеологія, медицина: сучасний стан та перспективи розвитку : тези доповідей Всеукраїнської науково-практичної інтернет-конференції (06 квітня 2021 р.) ANALYSIS OF EXPERIENCE COUNTRIES OF THE WORLD ON LEGALIZATION OF MEDICAL CANNABIS Nemchenko A. S., Kurylenko Y. E., Kuzmenko A. A. National University of Pharmacy, Kharkiv, Ukraine [email protected] Introduction. The WHO estimates that 1.2 billion people worldwide suffer from diseases in which medical cannabis has therapeutic value. The global world cannabis market (regulated and illegal) is estimated at $ 344 billion. USA. The five largest regional markets include: Asia ($ 132.9 billion), North America ($ 85.6 billion), Europe ($ 68.5 billion), Africa (37, $ 3 billion), Latin America ($ 9.8 billion). That is, the development of the cannabis industry is promising in terms of state regulation by the authorities in order to fill the budget and economic development of countries. The purpose of the study is to analyze the experience of countries around the world that have already legalized medical cannabis. Research materials: data from the official websites of the WHO, "American medical marijuana association", "European medicinal cannabis association". Results and discussion. For the analysis, we selected countries with a high level of GDP which have successfully legalized medical cannabis. The analysis found that in the United States, the majority of the 50 states, namely 36, legalized cannabis for medical use. From a historical point of view, in 1985, 23% of the total population consumed this substance. In 2015, cannabis consumption increased to 48%, and in 2018, 62% of the US population used cannabis. In 2019, consumption decreased by 15%.
    [Show full text]
  • Cannabis Control in Europe
    EMCDDA MONOGRAPHS A cannabis reader: global issues and local experiences Perspectives on cannabis controversies, treatment and regulation in Europe Editors Sharon Rödner Sznitman, Börje Olsson, Robin Room 8 OLUME I V Legal notice This publication of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is protected by copyright. The EMCDDA accepts no responsibility or liability for any consequences arising from the use of the data contained in this document. The contents of this publication do not necessarily reflect the official opinions of the EMCDDA's partners, any EU Member State or any agency or institution of the European Union or European Communities. A great deal of additional information on the European Union is available on the Internet. It can be accessed through the Europa server (http://europa.eu). Europe Direct is a service to help you find answers to your questions about the European Union Freephone number: 00 800 6 7 8 9 10 11 This publication should be referenced as: EMCDDA (2008), A cannabis reader: global issues and local experiences, Monograph series 8, Volume 1, European Monitoring Centre for Drugs and Drug Addiction, Lisbon. References to chapters in this monograph should include, where relevant, references to the authors of each chapter, together with a reference to the wider publication. For example: Corrigan, D. (2008), ‘The pharmacology of cannabis: issues for understanding its use’, in: A cannabis reader: global issues and local experiences, Monograph series 8, Volume 1, European Monitoring Centre for Drugs and Drug Addiction, Lisbon. The publication is available on the Internet at: http://www.emcdda.europa.eu/publications/monographs/cannabis Cataloguing data can be found at the end of this publication.
    [Show full text]
  • Development Over Time of the Population-Attributable Risk Fraction for Cannabis Use Disorder in Schizophrenia in Denmark
    Research JAMA Psychiatry | Original Investigation Development Over Time of the Population-Attributable Risk Fraction for Cannabis Use Disorder in Schizophrenia in Denmark Carsten Hjorthøj, PhD; Christine Merrild Posselt, MSc; Merete Nordentoft, DrMedSc Editorial IMPORTANCE Cannabis use and potency of cannabis have increased during the past 2 Multimedia decades. If the association between cannabis use and schizophrenia is causal, this should be reflected in an increase in the proportion of cases of schizophrenia being attributable to Supplemental content cannabis, the population-attributable risk fraction (PARF). OBJECTIVE To determine whether the PARF for cannabis use disorder in schizophrenia has increased over time. DESIGN, SETTING, AND PARTICIPANTS This nationwide, register-based historical prospective cohort study included all people in Denmark born before December 31, 2000, who were alive and 16 years or older at some point from January 1, 1972, to December 31, 2016. Data analysis was performed from August 2020 to April 2021. EXPOSURE Diagnosis of cannabis use disorder. MAIN OUTCOMES AND MEASURES Diagnosis of schizophrenia, with estimated PARF of cannabis use disorder in schizophrenia from 1972 to 2016. RESULTS A total of 7 186 834 individuals were included in the analysis, including 3 595 910 women (50.0%) and 3 590 924 men (50.0%). The adjusted hazard ratio for schizophrenia Author Affiliations: Copenhagen fluctuated at approximately 4 (with 95% CIs ranging from approximately 3 to 6) throughout Research Center for Mental Health–
    [Show full text]